Can anything shut down the Gold rally?
GENEVA - Ondine Biomedical Inc. (AIM:OBI) presented data showing its Steriwave nasal photodisinfection therapy reduced surgical site infections (SSIs) by 70% in hip and knee arthroplasties compared to using Octenisan nasal gel alone, according to a presentation at the International Conference on Prevention & Infection Control.
The company shared findings from the Mid Yorkshire Hospitals NHS Trust and analysis by the York Health Economics Consortium during Thursday’s conference in Geneva. The data also indicated a 52% lower SSI incidence with Steriwave across surgical specialties compared to mupirocin in published literature.
The health economic analysis suggested potential annual cost savings exceeding £190 million in the UK healthcare system. According to the presentation, implementing Steriwave could prevent over 40,000 SSIs annually in the UK by reducing hospital readmissions and extended patient stays.
Steriwave involves a five-minute application immediately before surgery, contrasting with traditional approaches requiring patients to apply ointments at home for days.
"SSIs are among the most devastating and costly hospital-acquired infections," said Dr. Simon Sinclair, Chief Medical Officer of Ondine Biomedical, in the press release statement.
The company reported that SSIs typically add an average of 9.7 extra days in hospital, require 45-75 additional staff hours per major case, and increase mortality risk by 2 to 11-fold.
Ondine has previously presented at ICPIC conferences, including research on Steriwave’s effectiveness against multidrug-resistant fungi, COVID-19 transmission, and extensively drug-resistant gram-negative bacteria.
The information presented is based on a company press release.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.